1. Home
  2. TOUR vs LCTX Comparison

TOUR vs LCTX Comparison

Compare TOUR & LCTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TOUR
  • LCTX
  • Stock Information
  • Founded
  • TOUR 2006
  • LCTX 1990
  • Country
  • TOUR China
  • LCTX United States
  • Employees
  • TOUR N/A
  • LCTX N/A
  • Industry
  • TOUR Transportation Services
  • LCTX Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • TOUR Consumer Discretionary
  • LCTX Health Care
  • Exchange
  • TOUR Nasdaq
  • LCTX Nasdaq
  • Market Cap
  • TOUR 101.0M
  • LCTX 107.3M
  • IPO Year
  • TOUR 2014
  • LCTX N/A
  • Fundamental
  • Price
  • TOUR $0.91
  • LCTX $0.66
  • Analyst Decision
  • TOUR
  • LCTX Strong Buy
  • Analyst Count
  • TOUR 0
  • LCTX 5
  • Target Price
  • TOUR N/A
  • LCTX $4.20
  • AVG Volume (30 Days)
  • TOUR 122.4K
  • LCTX 1.1M
  • Earning Date
  • TOUR 06-12-2025
  • LCTX 05-13-2025
  • Dividend Yield
  • TOUR 3.96%
  • LCTX N/A
  • EPS Growth
  • TOUR N/A
  • LCTX N/A
  • EPS
  • TOUR 0.09
  • LCTX N/A
  • Revenue
  • TOUR $70,367,853.00
  • LCTX $9,557,000.00
  • Revenue This Year
  • TOUR $16.99
  • LCTX N/A
  • Revenue Next Year
  • TOUR $13.23
  • LCTX $232.66
  • P/E Ratio
  • TOUR $10.54
  • LCTX N/A
  • Revenue Growth
  • TOUR 16.40
  • LCTX 19.42
  • 52 Week Low
  • TOUR $0.71
  • LCTX $0.37
  • 52 Week High
  • TOUR $1.76
  • LCTX $1.15
  • Technical
  • Relative Strength Index (RSI)
  • TOUR 46.11
  • LCTX 66.01
  • Support Level
  • TOUR $0.88
  • LCTX $0.48
  • Resistance Level
  • TOUR $0.94
  • LCTX $0.70
  • Average True Range (ATR)
  • TOUR 0.03
  • LCTX 0.05
  • MACD
  • TOUR -0.00
  • LCTX 0.02
  • Stochastic Oscillator
  • TOUR 25.44
  • LCTX 69.26

About TOUR Tuniu Corporation

Tuniu Corp is an online leisure travel company. The company is engaged in the provision of travel-related services in the People's Republic of China. It offers a large selection of packaged tours, including organized tours and self-guided tours, as well as travel-related services for leisure travelers. The company's organized tours provide pre-arranged itineraries, transportation, accommodations, entertainment, meals, and tour guide services. Its self-guided tours consist of combinations of flights and hotel bookings and other optional add-ons. The company derives almost all of its revenue from PRC.

About LCTX Lineage Cell Therapeutics Inc.

Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline is based on two platform technologies including cell replacement and cell/drug delivery. Lineage Cell's product candidate is OpRegen, a retinal pigment epithelium transplant therapy for the treatment of dry age-related macular degeneration, OPC1, an oligodendrocyte progenitor cell therapy for acute spinal cord injuries, and VAC2, allogeneic cancer immunotherapy of antigen-presenting dendritic cells for non-small cell lung cancer, ANP1, an allogeneic auditory neuron progenitor cells transplant for hearing loss, and PNC1, an allogeneic photoreceptor cell transplant for vision loss.

Share on Social Networks: